GLP‑1 medications have rewritten what's possible in weight loss. Semaglutide and tirzepatide — the molecules behind Ozempic, Wegovy, Mounjaro and Zepbound — routinely take 15–20% of body weight off in clinical trials, numbers that used to require surgery. But anyone who has actually used one knows the harder question arrives later: what happens when you stop? A 2025 review in the journal Biomedicines argues that the answer isn't another prescription. It's a lifestyle the medication can hand the work off to — and the authors single out intermittent fasting as the most natural partner.
This is the first thing we wanted to write about at Omadic, because it's the idea the whole app is built around. Here's what the science actually says — and, just as importantly, what it doesn't.
The problem GLP‑1s don't solve on their own
GLP‑1 receptor agonists are remarkably effective while you take them. The review summarizes the headline trials: semaglutide 2.4 mg produced a mean −14.9% weight loss in STEP‑1, and tirzepatide reached up to −20.9% in SURMOUNT‑1, with more than half of participants losing at least a fifth of their body weight. The SELECT trial even showed a ~20% relative‑risk reduction in major cardiovascular events. These are genuinely landmark results.
The catch is durability. When the medication stops, appetite returns and the weight tends to follow it back up — the STEP‑4 trial is the classic illustration of post‑discontinuation regain. It isn't a willpower failure; it's biology. The drug quiets hunger, and once it's gone, hunger comes back — so without new habits already in place, the body drifts toward where it started. And people do stop: the review cites real‑world discontinuation rates of up to 50% within two years, which it attributes largely to gastrointestinal side effects. Cost is a major barrier too — often $800–$1,200 a month in the US — alongside injection fatigue and the simple fact that nobody wants to inject forever.
There's a second, quieter problem. Rapid weight loss from a GLP‑1 isn't all fat. The review notes that these drugs produce measurable absolute loss of lean mass alongside fat — and muscle is exactly the tissue that keeps your metabolism high and helps the weight stay off. Lose too much of it and you've made the rebound easier, not harder.
So the medication is a powerful tool, but on its own it's a tool with an expiration date. That's the gap the review tries to close.
What the 2025 review actually proposes
The paper — "Added Value to GLP‑1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes," by Dragos Cozma, Cristina Văcărescu and Claudiu Stoicescu — is a narrative review, not a new clinical trial. That distinction matters, and we'll come back to it. What the authors offer is a translational framework: a structured way to combine GLP‑1 therapy with intermittent fasting and lifestyle change so that the results last beyond the prescription.
Their core argument is that the two interventions are complementary, not redundant. A GLP‑1 works mainly by suppressing appetite. Intermittent fasting works mainly by changing your metabolism. Stack them thoughtfully, the authors propose, and you may be able to lose weight more durably, preserve lean mass, improve tolerability, and reduce long‑term dependence on the drug — using the medication as a bridge to a sustainable routine rather than a permanent crutch.
What "intermittent fasting" means here
Intermittent fasting isn't one diet — it's a spectrum of eating schedules, and the review treats it that way. The gentlest end is time‑restricted eating: keeping all of your food inside a daily window, often 16 hours fasting and 8 hours eating (16:8), then narrowing toward 18:6, 20:4, and eventually one meal a day (OMAD) as it gets easier. The review notes that even a straightforward 8‑hour eating window produced about a −2.6% weight loss in one study, and that alternate‑day fasting improved blood pressure and lipid profiles while raising ketone levels.
None of that requires heroics. The principle — and it's the one Omadic is built on — is that you start where you are and extend the window only when each stage feels comfortable. Paired with a GLP‑1's appetite suppression, that progression is meant to feel almost effortless, because the medication is quieting the hunger that would normally make a longer fast hard to hold.
Why fasting and GLP‑1s may fit together
Appetite suppression makes fasting windows easier
The hardest part of intermittent fasting is the first few hungry hours — the willpower tax that makes people quit. The review points out that this is exactly what a GLP‑1 blunts. By reducing hunger and "food‑cue reactivity," the medication eases entry into fasting windows. In other words, the drug removes the single biggest barrier to the habit you're trying to build. On the flip side, intermittent fasting's own weight‑loss numbers are more modest on their own — roughly 3–8% over 6–12 months — and it has high dropout, around 40–50% in some studies. Each intervention is strongest precisely where the other is weakest.
Fasting flips switches the drug doesn't
Where a GLP‑1 quiets appetite, fasting reaches into cellular metabolism. The review describes fasting activating fat oxidation, ketogenesis, autophagy and insulin sensitization, engaging the AMPK–mTOR–sirtuin nutrient‑sensing pathways that govern how cells repair and recycle themselves. The authors go further, linking these same mechanisms to longevity — autophagy, mitochondrial biogenesis and the cell's nutrient‑sensing pathways — and suggesting these interventions "could extend not only years of life but also years of healthy life." That part is speculative, but the underlying point is concrete: appetite suppression and metabolic switching are different levers pulling in the same direction.
Structure that outlasts the prescription
There's a behavioral angle too. Fasting imposes time boundaries and routine — what the review calls "behavioral scaffolding" — that can reinforce the medication's effects and, crucially, remain in place after the drug is gone. The drug changes your biology for as long as you take it; the habits change your behavior for good.
Protecting muscle: the part most people miss
If there's one practical takeaway from the review, it's this: the combination only works if you protect your muscle. Both GLP‑1s and aggressive fasting can erode lean mass, and doing them together without a plan could compound that.
The fix the authors prescribe is straightforward and well‑supported:
- Lead with protein during your eating window, prioritizing leucine‑rich sources that drive muscle protein synthesis.
- Add resistance training, which supports the anabolic signaling that keeps muscle on your frame.
The review highlights a 2023 trial (Sandsdal and colleagues) in which exercise combined with a GLP‑1 led to greater reductions in abdominal fat and better metabolic outcomes than the GLP‑1 alone. The lesson generalizes: a GLP‑1 plus fasting plus protein plus lifting isn't four separate diets — it's one strategy where each piece covers a weakness in the others. Skip the protein and the training, and you risk losing the very tissue that protects your result.
A phased plan: bridge, transition, maintain
The review's framework isn't "fast and inject at the same time on day one." It's sequenced, designed to line up the medication's appetite suppression with the slow work of building habits:
- Bridge. Start on the GLP‑1, when hunger is lowest, and use that window to establish fasting and a protein‑forward eating pattern while it's genuinely easy.
- Transition. Lock in the routine — consistent eating windows, resistance training, adequate protein — so the behavior is solid before anything changes.
- Maintain. As you and your prescriber taper the medication, the fasting routine and lifestyle carry the result, so the weight doesn't come straight back.
It's the difference between using a GLP‑1 as a destination and using it as an on‑ramp. The medication buys you the one thing almost every lifestyle change needs and rarely gets: a stretch of months when sticking to the plan is genuinely easy, because the hunger that usually derails people has been turned down. The review's bet is that if you spend that window building the right habits — the windows, the protein, the training — they're still standing when the prescription ends.
The honest caveats
This is where we have to be careful, and the authors are too. No clinical trial has yet tested this combination head‑to‑head. The review is explicit that, absent that evidence, "any discussion of synergy remains conceptual." It makes a strong biological and practical case — but a case is not proof, and the paper itself calls for the randomized trials that would settle it.
There are real risks to respect, as well:
- Overlapping side effects. GLP‑1s commonly cause nausea, early satiety and reflux. The review warns these "could theoretically be intensified when combined with prolonged fasting windows." Longer is not automatically better.
- Disordered eating. Restrictive eating patterns can trigger binge–restrict cycles or worse in vulnerable people. This combination is not for everyone.
- Blood‑sugar risk. Anyone taking insulin or other glucose‑lowering medication can risk hypoglycemia while fasting.
Fasting isn't right for everyone — and especially not if you're pregnant, breastfeeding, managing diabetes, or have a history of disordered eating. If you're on a GLP‑1, work with your prescriber before changing your dose or your eating schedule. Omadic is coaching and education, not medical advice, and it doesn't prescribe or change medication.
How Omadic is built for exactly this
The phased model in this review is, almost line for line, the approach Omadic was designed to deliver. Guided fasting plans that start where you are and grow with you. A medication and supplement tracker that follows your GLP‑1 dose, titration and reminders right alongside your fasting. Calorie and protein tracking so you actually hit the targets that protect your muscle. Real‑time alerts on your watch. And licensed‑nurse coaching to help you do it safely — including a dedicated GLP‑1 off‑ramp program that uses the same progression to ease you toward one meal a day as you taper, so your results hold when you come off.
GLP‑1s are the tool. The lifestyle is what makes it last. The science is still catching up to the combination — but the rationale is strong, and it's the bet we're making.
New to fasting? Start with how to break a fast the right way and why electrolytes matter on longer fasts.
Sources
- Cozma D, Văcărescu C, Stoicescu C. Added Value to GLP‑1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes. Biomedicines. 2025;13(12):3079. Journal (MDPI) · Full text (PubMed Central)
- Trials summarized within the review above: Wilding et al., STEP‑1 (semaglutide), New England Journal of Medicine, 2021; Jastreboff et al., SURMOUNT‑1 (tirzepatide), New England Journal of Medicine, 2022; Lincoff et al., SELECT (cardiovascular outcomes), New England Journal of Medicine, 2023; Rubino et al., STEP‑4 (weight regain after discontinuation), JAMA, 2021.
- de Cabo R, Mattson MP. Effects of Intermittent Fasting on Health, Aging, and Disease. New England Journal of Medicine, 2019 — the foundational review of intermittent fasting mechanisms referenced throughout.